Biophan Announces Online Availability of New Medical Design Technology Interview on Company's Leading Biomedical Technology
|Q&A Features CEO Michael Weiner on Biophan's Nanotechnology-Based Solutions to Make Medical Devices Safe and Image Compatible with MRI|
“We offer competitive advantages to solve problems that can improve the functionality and utility of medical devices for the manufacturers”
Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, announced today the online availability of a new "Q&A"-style interview in the respected trade magazine, Medical Design Technology.
The interview highlights the Company's novel nanotechnology-based solutions for safe and image compatible Magnetic Resonance Imaging (MRI) of medical devices and provides insights into the large global marketplace for these solutions. It also discusses the ways in which the Company's technologies are changing the competitive landscape.
Biophan has developed a wide range of MRI-enabling technologies for pacemakers, defibrillators, neurostimulators, catheters, guidewires, drug pumps, and other devices. The Company provides its innovations and technologies to medical device manufacturers for incorporation into their product lines. Several of the Company's primary solutions involve nanotechnology and thin film coatings.
Currently, due to serious safety problems, millions of people with pacemakers, neurostimulators, and other devices cannot be exposed to the MRI environment. "We offer competitive advantages to solve problems that can improve the functionality and utility of medical devices for the manufacturers," Mr. Weiner says in the interview. "For example, for a manufacturer to have the first safe pacemaker is a competitive advantage that can translate into increased market share."
Biophan's mission is to develop technologies to improve medical devices and to bring these technologies to market through strategic partnerships. Biophan recently signed a landmark agreement to license some of its proprietary technologies to global medical device manufacturer Boston Scientific (NYSE: BSX). Biophan is also in discussions with other major medical device manufacturers.
To view the article, please visit http://www.biophan.com/newsroom2.php.
About Medical Design Technology Magazine
Medical Design Technology keeps the medical device manufacturing industry up to date with the latest developments in this growing and increasingly competitive field. Medical Design Technology reaches 41,000 production managers, R&D engineers and corporate managers who spend over $64 billion annually to complete their design projects. For more information, please visit: http://www.mdtmag.com/scripts/digital.asp
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 144 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 94 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.